Assyro Team
Published March 14, 2026
Updated April 8, 2026
16 min read
eCTD Module 3: Quality (CMC) Documentation Complete Guide
Quick Answer
eCTD Module 3 contains the Chemistry, Manufacturing, and Controls (CMC) documentation for a drug application. It is organized into four main sections: 3.2.S (Drug Substance), 3.2.P (Drug Product), 3.2.A (Appendices), and 3.2.R (Regional Information). Module 3 follows the CTD quality structure described in ICH M4Q(R1), and post-approval manufacturing changes often require corresponding Module 3 updates.
Key Takeaways
Key Takeaways
- Module 3 is organized into 3.2.S (Drug Substance), 3.2.P (Drug Product), 3.2.A (Appendices), and 3.2.R (Regional Information), following ICH M4Q(R1).
- ICH Q1A(R2) defines standard long-term, intermediate, and accelerated stability study conditions, but the amount of data needed at filing depends on the product and the shelf-life or retest-period proposal being supported.
- Impurity identification and qualification thresholds are defined by ICH Q3A(R2) for drug substance and ICH Q3B(R2) for drug product; mutagenic impurity limits follow ICH M7(R2).
- Post-approval CMC changes are managed through the applicable reporting category under 21 CFR 314.70 and usually require targeted Module 3 updates.
- eCTD Module 3 is the quality module of the Common Technical Document. It contains the complete CMC data package for both the drug substance (active pharmaceutical ingredient) and the drug product (finished dosage form). For regulatory reviewers, Module 3 answers a fundamental question: can this drug be manufactured consistently, to appropriate quality standards, with adequate controls to ensure patient safety?
- Module 3 is governed by ICH M4Q(R1), "Quality Overall Summary of Module 2 / Module 3: Quality." The detailed technical content within Module 3 draws on numerous ICH quality guidelines, including Q1-Q14, which define specific requirements for stability, impurities, specifications, analytical validation, and pharmaceutical development. Understanding proper document granularity is essential for organizing Module 3 content efficiently.
- In this guide, you will learn:
- The complete structure of Module 3 (every section and sub-section)
- Drug substance (3.2.S) documentation requirements in detail
- Drug product (3.2.P) documentation requirements in detail
- Appendix and regional information requirements
- Common Module 3 deficiencies that lead to FDA Information Requests or Complete Response Letters
Module 3 Structure Overview
High-Level Organization
| Section | Title | Scope |
|---|---|---|
| 3.1 | Table of Contents | Module 3 document listing |
| 3.2.S | Drug Substance | Active pharmaceutical ingredient CMC |
| 3.2.P | Drug Product | Finished dosage form CMC |
| 3.2.A | Appendices | Facilities, adventitious agents, novel excipients |
| 3.2.R | Regional Information | Region-specific quality information |
Multiple Drug Substances or Drug Products
Module 3 accommodates products with multiple active ingredients or multiple dosage forms:
- For combination products with two or more drug substances, a separate 3.2.S section is prepared for each
- For applications covering multiple strengths or dosage forms, a separate 3.2.P section is prepared for each
- Cross-references between drug substance sections and the drug product section must be clear
Section 3.2.S: Drug Substance
Section 3.2.S contains all CMC information for the active pharmaceutical ingredient (API). Each sub-section addresses a specific aspect of drug substance quality.
3.2.S.1: General Information
| Sub-Section | Content |
|---|---|
| 3.2.S.1.1 Nomenclature | INN, USAN, chemical name, laboratory code, CAS number |
| 3.2.S.1.2 Structure | Molecular formula, molecular weight, structural formula (including stereochemistry), physicochemical properties |
| 3.2.S.1.3 General Properties | Physical form, solubility, partition coefficient, dissociation constants, polymorphism, hygroscopicity |
3.2.S.2: Manufacture
This section describes how the drug substance is made, who makes it, and how the process is controlled.
| Sub-Section | Content | Key ICH References |
|---|---|---|
| 3.2.S.2.1 Manufacturer(s) | Name, address, and responsibility of each manufacturer | - |
| 3.2.S.2.2 Description of Manufacturing Process and Process Controls | Process flow diagram, narrative description, process parameters, in-process controls, critical steps | ICH Q11 |
| 3.2.S.2.3 Control of Materials | Specifications and quality of starting materials, reagents, solvents, catalysts | ICH Q11 |
| 3.2.S.2.4 Controls of Critical Steps and Intermediates | Critical process parameters, intermediate specifications, acceptance criteria | ICH Q11, Q8(R2) |
| 3.2.S.2.5 Process Validation and/or Evaluation | Validation approach, results, ongoing process verification | ICH Q11 |
| 3.2.S.2.6 Manufacturing Process Development | Process development history, changes made, comparability data | ICH Q11, Q8(R2) |
“FDA Expectation: For NDAs, FDA expects a detailed manufacturing process description including:
“- Complete synthetic route with all steps from commercially available starting materials
“- Justification for starting material designation (per ICH Q11, Section 5)
“- Process parameters and proven acceptable ranges (PARs) for critical steps
“- In-process control tests and acceptance criteria
3.2.S.3: Characterisation
| Sub-Section | Content | Key ICH References |
|---|---|---|
| 3.2.S.3.1 Elucidation of Structure and Other Characteristics | Confirmation of structure by spectroscopic methods (NMR, MS, IR, UV), X-ray crystallography (if applicable), polymorphic form identification | - |
| 3.2.S.3.2 Impurities | Process-related impurities, degradation products, residual solvents (ICH Q3C(R8)), elemental impurities (ICH Q3D(R2)), genotoxic impurities (ICH M7(R2)) | ICH Q3A(R2), Q3C(R8), Q3D(R2), M7(R2) |
Impurity Thresholds per ICH Q3A(R2):
| Maximum Daily Dose | Reporting Threshold | Identification Threshold | Qualification Threshold |
|---|---|---|---|
| <=2 g/day | 0.05% | 0.10% or 1.0 mg/day (lower) | 0.15% or 1.0 mg/day (lower) |
| >2 g/day | 0.03% | 0.05% | 0.05% |
3.2.S.4: Control of Drug Substance
This section defines the specifications and analytical methods used to ensure drug substance quality.
| Sub-Section | Content | Key ICH References |
|---|---|---|
| 3.2.S.4.1 Specification | Table of tests, analytical procedures, and acceptance criteria | ICH Q6A, Q6B (biologics) |
| 3.2.S.4.2 Analytical Procedures | Description of each analytical method | ICH Q2(R2) |
| 3.2.S.4.3 Validation of Analytical Procedures | Validation data per ICH Q2(R2): accuracy, precision, specificity, LOD, LOQ, linearity, range, robustness | ICH Q2(R2) |
| 3.2.S.4.4 Batch Analyses | Certificate of analysis data for representative batches (minimum 3) | ICH Q6A |
| 3.2.S.4.5 Justification of Specification | Scientific rationale for each test and acceptance criterion | ICH Q6A |
Typical Drug Substance Specification Tests:
| Test | Method Type | Acceptance Criterion Example |
|---|---|---|
| Appearance | Visual | White to off-white powder |
| Identity | IR, HPLC retention time | Conforms to reference standard |
| Assay | HPLC | 98.0-102.0% |
| Related substances (impurities) | HPLC | Individual: NMT 0.15%; Total: NMT 1.0% |
| Residual solvents | GC-HS | Per ICH Q3C(R8) limits |
| Water content | Karl Fischer | NMT 0.5% |
| Heavy metals/elemental impurities | ICP-MS | Per ICH Q3D(R2) |
| Particle size | Laser diffraction | D90: NMT XX um (if relevant) |
| Chiral purity | Chiral HPLC | NLT 99.0% (if applicable) |
| Mutagenic impurities | LC-MS/MS | Per ICH M7(R2) TTC limits |
3.2.S.5: Reference Standards or Materials
Information on primary and secondary reference standards used for testing:
- Source of primary reference standard (e.g., USP, Ph. Eur., in-house)
- Certificate of analysis for primary reference standard
- Qualification procedure for secondary (working) standards
- Requalification frequency
3.2.S.6: Container Closure System
Description of the packaging used for the drug substance:
- Container material (e.g., HDPE drum, polyethylene bag)
- Closure system
- Specifications for container components
- Compliance with relevant pharmacopeial requirements
3.2.S.7: Stability
| Sub-Section | Content | Key ICH References |
|---|---|---|
| 3.2.S.7.1 Stability Summary and Conclusions | Summary of all stability data, proposed retest period | ICH Q1A(R2) |
| 3.2.S.7.2 Post-Approval Stability Protocol and Stability Commitment | Ongoing stability program for commercial batches | ICH Q1A(R2) |
| 3.2.S.7.3 Stability Data | Full stability study reports, tables, and trending | ICH Q1A(R2), Q1B |
ICH Q1A(R2) Common Storage Conditions:
| Condition | Temperature/Humidity | Purpose |
|---|---|---|
| Long-term | 25C/60% RH | Supports proposed retest period or shelf life |
| Intermediate | 30C/65% RH | Supplemental condition when relevant under Q1A(R2) |
| Accelerated | 40C/75% RH | Evaluates the effect of short-term stress on stability |
| Stress/forced degradation | Various (acid, base, oxidation, heat, light) | Supports understanding of degradation pathways |
| Photostability | ICH Q1B conditions | Evaluates light sensitivity |
Section 3.2.P: Drug Product
Section 3.2.P contains all CMC information for the finished dosage form.
3.2.P.1: Description and Composition of the Drug Product
| Content | Details |
|---|---|
| Dosage form description | Tablet, capsule, injection, etc.; physical appearance |
| Quantitative composition | Complete formulation table showing each component, function, and quantity per unit dose |
| Overages | Any manufacturing overages and justification |
| Type and function of excipients | Identification of each excipient and its role (filler, binder, lubricant, preservative, etc.) |
3.2.P.2: Pharmaceutical Development
This section documents the scientific rationale behind formulation and process design. Per ICH Q8(R2), it should follow Quality by Design (QbD) principles where applicable.
| Sub-Section | Content | Key ICH References |
|---|---|---|
| 3.2.P.2.1 Components of Drug Product | Compatibility studies, excipient selection rationale | ICH Q8(R2) |
| 3.2.P.2.2 Drug Product | Formulation development history, prototype studies, dissolution development | ICH Q8(R2) |
| 3.2.P.2.3 Manufacturing Process Development | Process selection, scale-up, critical process parameters (CPPs) | ICH Q8(R2), Q11 |
| 3.2.P.2.4 Container Closure System | Selection rationale, extractables/leachables studies (per FDA Guidance and USP <1663>/<1664>) | - |
| 3.2.P.2.5 Microbiological Attributes | Preservative effectiveness (if applicable), microbial limits rationale | USP <51>, <61>, <62> |
| 3.2.P.2.6 Compatibility | Compatibility with reconstitution diluents, IV bags/tubing (if applicable) | - |
3.2.P.3: Manufacture
| Sub-Section | Content |
|---|---|
| 3.2.P.3.1 Manufacturer(s) | Name, address, GMP status |
| 3.2.P.3.2 Batch Formula | Master formula for commercial batch size |
| 3.2.P.3.3 Description of Manufacturing Process and Process Controls | Process flow diagram, step descriptions, critical steps, in-process tests |
| 3.2.P.3.4 Controls of Critical Steps and Intermediates | CPPs, in-process controls, acceptance criteria |
| 3.2.P.3.5 Process Validation and/or Evaluation | Process validation protocol and results (or commitment) |
“FDA Note: For NDA submissions, FDA expects either completed process validation data (preferred) or a detailed process validation protocol with a commitment to complete validation before commercial launch. Per FDA Guidance, "Process Validation: General Principles and Practices" (January 2011), process validation follows three stages: Stage 1 (Process Design), Stage 2 (Process Qualification), and Stage 3 (Continued Process Verification).
3.2.P.4: Control of Excipients
| Sub-Section | Content |
|---|---|
| 3.2.P.4.1 Specifications | Pharmacopeial (USP, Ph. Eur., JP) or in-house specifications for each excipient |
| 3.2.P.4.2 Analytical Procedures | Methods for non-compendial tests |
| 3.2.P.4.3 Validation of Analytical Procedures | For non-compendial methods |
| 3.2.P.4.4 Justification of Specifications | Rationale for any non-compendial specifications |
| 3.2.P.4.5 Excipients of Human or Animal Origin | BSE/TSE risk assessment, viral safety (cross-reference to 3.2.A.2) |
| 3.2.P.4.6 Novel Excipients | Full CMC support for any excipient not previously used in an approved product (cross-reference to 3.2.A.3) |
3.2.P.5: Control of Drug Product
| Sub-Section | Content | Key ICH References |
|---|---|---|
| 3.2.P.5.1 Specification(s) | Release and shelf-life specifications | ICH Q6A/Q6B |
| 3.2.P.5.2 Analytical Procedures | Method descriptions | - |
| 3.2.P.5.3 Validation of Analytical Procedures | Validation per ICH Q2(R2) | ICH Q2(R2) |
| 3.2.P.5.4 Batch Analyses | COA for representative batches | ICH Q6A |
| 3.2.P.5.5 Characterisation of Impurities | Degradation product identification and qualification | ICH Q3B(R2) |
| 3.2.P.5.6 Justification of Specification(s) | Scientific rationale | ICH Q6A |
Typical Drug Product Specification Tests (Oral Solid):
| Test | Method | Acceptance Criterion Example |
|---|---|---|
| Appearance | Visual | White, round, film-coated tablets |
| Identity | HPLC, UV | Positive identification |
| Assay | HPLC | 95.0-105.0% of label claim |
| Dissolution | USP apparatus (I or II) | Q = 80% in 30 minutes |
| Related substances | HPLC | Individual: NMT 0.2%; Total: NMT 1.0% |
| Content uniformity | HPLC | Meets USP <905> |
| Water content | Karl Fischer | NMT 3.0% |
| Microbial limits | USP <61>/<62> | TAMC: NMT 1000 CFU/g; TYMC: NMT 100 CFU/g |
| Elemental impurities | ICP-MS | Per ICH Q3D(R2) / USP <232> |
3.2.P.6: Reference Standards
Same approach as 3.2.S.5 for the drug product.
3.2.P.7: Container Closure System
| Content | Details |
|---|---|
| Description | Material, dimensions, specifications |
| Suitability | Compatibility, protection, safety, performance |
| Specifications | Pharmacopeial or in-house specifications for container components |
| Child-resistant packaging | Compliance with PPPA requirements (if applicable) |
3.2.P.8: Stability
Follows the same structure as 3.2.S.7 but for the finished drug product.
| Storage Condition | Role in the dossier |
|---|---|
| 25C/60% RH (long-term) | Core stability condition for many general-case products under Q1A(R2) |
| 30C/65% RH (intermediate) | Supplemental condition when relevant under Q1A(R2) |
| 40C/75% RH (accelerated) | Short-term stress condition |
| In-use stability | Product-specific support for opened or reconstituted product, where relevant |
| Photostability | Light sensitivity assessment per ICH Q1B |
Section 3.2.A: Appendices
3.2.A.1: Facilities and Equipment
Manufacturing facility layouts, equipment lists, and capability descriptions. This section is particularly important for sterile products and biologics.
3.2.A.2: Adventitious Agents Safety Evaluation
Required when drug substance or excipients are derived from animal or human sources:
| Assessment | Applicable When |
|---|---|
| BSE/TSE risk assessment | Animal-derived materials (e.g., gelatin, stearic acid, lactose) |
| Viral safety evaluation | Cell-culture-derived biologics, human plasma derivatives |
| Mycoplasma testing | Cell-culture-derived products |
3.2.A.3: Novel Excipients
If the drug product contains an excipient not previously used in an approved drug product (or used by a new route of administration), a full CMC data package for that excipient must be provided, equivalent to a drug substance package (manufacture, characterization, control, stability).
Section 3.2.R: Regional Information
Region-specific quality data that does not fit into the harmonized sections:
| Region | Typical 3.2.R Content |
|---|---|
| FDA (US) | Drug Master File (DMF) references, executed batch records, method validation summaries |
| EMA (EU) | Active Substance Master File (ASMF) information, TSE certificate |
| Health Canada | Additional regional requirements per HC guidance |
Common Module 3 Review Issues
Drug Substance Deficiencies
| Deficiency | Root Cause |
|---|---|
| Inadequate starting material justification | Not following ICH Q11 principles |
| Insufficient impurity control | Missing identification or qualification for relevant impurities |
| Process validation gaps | Validation approach or supporting data is incomplete |
| Incomplete characterization | Important physical or chemical characteristics are not addressed |
| Residual solvent testing gaps | Solvents used in manufacture are not addressed appropriately |
| Inadequate stability support | Data does not adequately support the proposed retest period |
Drug Product Deficiencies
| Deficiency | Root Cause |
|---|---|
| Dissolution method not discriminating | Method does not detect meaningful quality changes |
| Insufficient process validation support | Validation approach or supporting data is incomplete |
| Container closure suitability not demonstrated | Compatibility or protective function is not adequately justified |
| Stability-indicating method not validated | Method cannot detect relevant degradation products |
| Specification justification is weak | Acceptance criteria are not tied clearly to development and manufacturing data |
| Scale-up comparability gaps | Commercial-scale material is not bridged adequately to development material |
Module 3 size varies widely by product complexity, manufacturing approach, and dosage form. A simple oral solid dossier is materially different from a sterile product, complex formulation, or biologic. The important point is to organize the dossier according to CTD granularity and make each section reviewable.
Key Regulatory References
| Reference | Citation |
|---|---|
| ICH M4Q(R1) | Quality Module CTD Structure |
| ICH Q1A(R2) | Stability Testing of New Drug Substances and Products |
| ICH Q1B | Photostability Testing |
| ICH Q2(R2) | Validation of Analytical Procedures |
| ICH Q3A(R2) | Impurities in New Drug Substances |
| ICH Q3B(R2) | Impurities in New Drug Products |
| ICH Q3C(R8) | Residual Solvents |
| ICH Q3D(R2) | Elemental Impurities |
| ICH Q6A | Specifications for New Drug Substances and New Drug Products |
| ICH Q6B | Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products |
| ICH Q8(R2) | Pharmaceutical Development |
| ICH Q11 | Development and Manufacture of Drug Substances |
| FDA Process Validation Guidance | January 2011 |
| NDA CMC Requirements | 21 CFR 314.50 |
| Post-Approval Changes | 21 CFR 314.70 |
References
About the author
Assyro Team
Expert regulatory operations consultants helping pharmaceutical companies navigate complex compliance challenges.
See Assyro in action
Catch eCTD and eSTAR errors before your FDA review cycle.
Book a 20-minute demo. We'll validate a sample of your submission live and show you exactly where Assyro catches what your current QC misses.